Tags : In-Licenses

Axsome In-Licenses Pfizer’s Reboxetine and Esreboxetine in the US

Shots: Pfizer to receive Axsome’s common shares of ~$8M, $3M in cash as upfront, ~$323M regulatory & commercial milestones and royalties in sales of the therapies and has right of first negotiation on any potential strategic transactions involving AXS-12 and AXS-14 Axsome to receive an exclusive license to Pfizer’s clinical, nonclinical data and intellectual property […]Read More

Bausch Health In-Licenses Clearside’s Xipere (triamcinolone acetonide suprachoroidal injectable suspension)

Shots: Clearside to receive ~$20M prior to launch including an up front and is eligible to receive commercial & regulatory milestones on approval of Xipere for an additional indication and royalties on sales in the licensed territories Bausch Health to get an exclusive license to develop & commercialize Xipere for macular edema associated with uveitis […]Read More